A brain penetrating form of human EPO has been developed wherein EPO is fused to a chimeric monoclonal antibody (MAb) against the mouse transferrin receptor (TfR), which is designated as the cTfRMAb-EPO fusion protein.
HLB developed the anti-EPO antibodies assay, its validation, and tested the patient's samples.
For patients with diabetic nephropathy or for those who develop anaemia following chemotherapy, activation of EPO-Rs with ESAs could promote accelerated retinopathy or tumour vascularisation respectively.
Networks of EPO-treated primary hippocampal neurons develop lower overall spiking activity but enhanced bursting in discrete neuronal assemblies.
EPO was at the center of the Tour de France drug scandal in 1998, which led to enormous pressure by international governments for the I.O.C. to develop a reliable method to detect the drug's use.
None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period.
In this study, a biphasic cultivation strategy for a Chinese hamster ovary (CHO) cell line expressing an erythropoietin fusion protein (Epo-Fc) was developed.
EPO-Z was developed and registered in agreement with the European Medicines Agency EMEAA) guidelines.
Scientists associated with Warren Pharmaceuticals, a small, privately held biotechnology company in Ossining, N.Y., say they have developed a chemically modified version of EPO that does not increase red blood cell levels but, in animals, still protects tissues from damage.
But the relationship has been stormy, and Amgen has developed a longer-lasting version of EPO, called Aranesp, that it is allowed to sell in Europe, in competition with Eprex.
